The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group.
The company makes ultrasound, x-ray and MRI contrast media, drugs for treating cancer, multiple-sclerosis, heart and nervous system disorders and severe skin conditions.
In general, its activities are focused on four business areas: Fertility control & hormone therapy, diagnostics & radiopharmaceuticals, dermatology as well as specialized therapeutics for disabling diseases in the fields of the central nervous system, oncology and cardiovascular system.
Currently, Bayer Schering Pharma discontinued the manufacturing and development of ultrasound contrast agents.

Ultrasound Contrast Agents:

A bolus is a rapid infusion of high dose contrast agent. Dynamic and accumulation phase imaging can be performed after bolus injection. Since the transit time of the bolus is only a short time, images with high frame rate show the wash in and wash out of the contrast material. The injection rate and the total injected volume modifies the bolus peak profile. Substantial changes in the concentrations during signal acquisition induce artifacts. Furthermore, the hemodynamic parameters (cardiac output, blood pressure) influence the bolus profile. However, the characteristics of ultrasound contrast agents are favorable with a continuous perfusion.

See also Negative Bolus.

Echogenicity is the ability of a medium to create an echo, for example to return a signal when tissue is in the path of the sound beam. The ultrasound echogenicity is dependent on characteristics of tissues or contrast agents and is measured by calculating the backscattering and transmission coefficients as a function of frequency.
The fundamental parameters that determine echogenicity are density and compressibility. Blood is two to three orders of magnitude less echogenic than tissue due to the relatively small impedance differences between red blood cells and plasma. The tissue echogenicity can be increased by ultrasound contrast agents. Encapsulated microbubbles are highly echogenic due to differences in their compressibility and density, compared to tissue or plasma.
Microbubbles are 10,000 times more compressible than red blood cells. The compressibility of air is 7.65 x 10−6 m2/N, in comparison with 4.5 x 10-11 m2/N for water (on the same order of magnitude as tissue and plasma). This impedance mismatch results in a very high echogenicity. An echo from an individual contrast agent can be detected by a clinical ultrasound system sensitive to a volume on the order of 0.004 pl.

See also Isoechogenic, Retrolenticular Afterglow, and Sonographic Features.

(HPD) Harmonic power Doppler is currently one of the most sensitive techniques for detecting ultrasound contrast agents. HPD works by transmitting multiple pulses toward the object to be imaged and detecting the pulse-to-pulse changes in the received echo signals.
Second harmonic bandbass filtering is applied to the received signals to exploit the non-linear behavior of scattering from bubbles (clutter). Harmonic power Doppler operates best at high output levels because of increased contrast destruction, and pulse amplitudes close to the maximum allowed are used much of the time.
With a high mechanical index, non-linear propagation of the sound will cause significant harmonic components from tissue, and the contrast agent to tissue ratio will decrease.
Also called Harmonic Power Angio. See also Multiple Frame Trigger.

The earliest introduction of vascular ultrasound contrast agents (USCA) was by Gramiak and Shah in 1968, when they injected agitated saline into the ascending aorta and cardiac chambers during echocardiographic to opacify the left heart chamber. Strong echoes were produced within the heart, due to the acoustic mismatch between free air microbubbles in the saline and the surrounding blood.